Cargando…

Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ

BACKGROUND: Interferon (IFN) therapy can cause significant side effects in chronic hepatitis C (CHC) patients; however, the health-related quality of life (HRQOL) of antiviral-treated CHC patients has not been established in Taiwan. This study evaluated domains and the degree to which antiviral trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Shu-Chuan, Yang, Sheng-Shun, Chang, Chiu-Chun, Lin, Chun-Che, Chung, Yueh-Chin, Li, Tsai-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073178/
https://www.ncbi.nlm.nih.gov/pubmed/24941994
http://dx.doi.org/10.1186/1477-7525-12-97
_version_ 1782323088060317696
author Chang, Shu-Chuan
Yang, Sheng-Shun
Chang, Chiu-Chun
Lin, Chun-Che
Chung, Yueh-Chin
Li, Tsai-Chung
author_facet Chang, Shu-Chuan
Yang, Sheng-Shun
Chang, Chiu-Chun
Lin, Chun-Che
Chung, Yueh-Chin
Li, Tsai-Chung
author_sort Chang, Shu-Chuan
collection PubMed
description BACKGROUND: Interferon (IFN) therapy can cause significant side effects in chronic hepatitis C (CHC) patients; however, the health-related quality of life (HRQOL) of antiviral-treated CHC patients has not been established in Taiwan. This study evaluated domains and the degree to which antiviral treatment affects the HRQOL in CHC patients and identifies factors associated with variations between patients. METHODS: Health-related quality of life (HRQOL) was assessed using the Short Form-36 (SF-36) and the Chronic Liver Disease Questionnaire (CLDQ) in 108 antiviral-treated CHC patients. Eight scales and two summary scales of the SF-36 were compared with 256 age- and gender-matched population norms and 64 age- and gender-matched CHC patients without antiviral therapy. Descriptive statistic measures, one-way ANOVA, and regression analysis were used for data analysis. RESULTS: (1) CHC patients receiving antiviral treatment displayed significantly lower scores in six scales, the Physical Component Summary (PCS), and the Mental Component Summary (MCS) of the SF-36, when compared to the population norms and patients without antiviral therapy (p < 0.05). (2) The mean CLDQ score of antiviral-treated patients was lower than that of patients without antiviral therapy, including subscales of ‘fatigue’, ‘systemic symptoms’, and ‘role emotion’. (3) All SF-36 subscales significantly correlated with all CLDQ subscales, with the greatest correlation coefficients shown between fatigue and vitality and mental health of SF-36. (4) Antiviral therapy had a greater negative impact on females in the CLDQ, on all patients during treatment weeks 9–16 in the PCS and on patients with a monthly income of less than NT$10,000 in the CLDQ, PCS, and MCS. CONCLUSIONS: This study highlighted impairments in the quality of life of chronic hepatitis C patients treated with IFN-based therapy. The significant factors associated with HRQOL include gender, income, and treatment duration. The results of this study might provide nurses with a comprehensive understanding of HRQOL and its determining factors in antiviral-treated CHC patients. The findings can serve as a useful reference for nursing personnel in developing instructions for upgrading the care of CHC patients.
format Online
Article
Text
id pubmed-4073178
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40731782014-06-28 Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ Chang, Shu-Chuan Yang, Sheng-Shun Chang, Chiu-Chun Lin, Chun-Che Chung, Yueh-Chin Li, Tsai-Chung Health Qual Life Outcomes Research BACKGROUND: Interferon (IFN) therapy can cause significant side effects in chronic hepatitis C (CHC) patients; however, the health-related quality of life (HRQOL) of antiviral-treated CHC patients has not been established in Taiwan. This study evaluated domains and the degree to which antiviral treatment affects the HRQOL in CHC patients and identifies factors associated with variations between patients. METHODS: Health-related quality of life (HRQOL) was assessed using the Short Form-36 (SF-36) and the Chronic Liver Disease Questionnaire (CLDQ) in 108 antiviral-treated CHC patients. Eight scales and two summary scales of the SF-36 were compared with 256 age- and gender-matched population norms and 64 age- and gender-matched CHC patients without antiviral therapy. Descriptive statistic measures, one-way ANOVA, and regression analysis were used for data analysis. RESULTS: (1) CHC patients receiving antiviral treatment displayed significantly lower scores in six scales, the Physical Component Summary (PCS), and the Mental Component Summary (MCS) of the SF-36, when compared to the population norms and patients without antiviral therapy (p < 0.05). (2) The mean CLDQ score of antiviral-treated patients was lower than that of patients without antiviral therapy, including subscales of ‘fatigue’, ‘systemic symptoms’, and ‘role emotion’. (3) All SF-36 subscales significantly correlated with all CLDQ subscales, with the greatest correlation coefficients shown between fatigue and vitality and mental health of SF-36. (4) Antiviral therapy had a greater negative impact on females in the CLDQ, on all patients during treatment weeks 9–16 in the PCS and on patients with a monthly income of less than NT$10,000 in the CLDQ, PCS, and MCS. CONCLUSIONS: This study highlighted impairments in the quality of life of chronic hepatitis C patients treated with IFN-based therapy. The significant factors associated with HRQOL include gender, income, and treatment duration. The results of this study might provide nurses with a comprehensive understanding of HRQOL and its determining factors in antiviral-treated CHC patients. The findings can serve as a useful reference for nursing personnel in developing instructions for upgrading the care of CHC patients. BioMed Central 2014-06-18 /pmc/articles/PMC4073178/ /pubmed/24941994 http://dx.doi.org/10.1186/1477-7525-12-97 Text en Copyright © 2014 Chang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chang, Shu-Chuan
Yang, Sheng-Shun
Chang, Chiu-Chun
Lin, Chun-Che
Chung, Yueh-Chin
Li, Tsai-Chung
Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
title Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
title_full Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
title_fullStr Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
title_full_unstemmed Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
title_short Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
title_sort assessment of health-related quality of life in antiviral-treated taiwanese chronic hepatitis c patients using sf-36 and cldq
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073178/
https://www.ncbi.nlm.nih.gov/pubmed/24941994
http://dx.doi.org/10.1186/1477-7525-12-97
work_keys_str_mv AT changshuchuan assessmentofhealthrelatedqualityoflifeinantiviraltreatedtaiwanesechronichepatitiscpatientsusingsf36andcldq
AT yangshengshun assessmentofhealthrelatedqualityoflifeinantiviraltreatedtaiwanesechronichepatitiscpatientsusingsf36andcldq
AT changchiuchun assessmentofhealthrelatedqualityoflifeinantiviraltreatedtaiwanesechronichepatitiscpatientsusingsf36andcldq
AT linchunche assessmentofhealthrelatedqualityoflifeinantiviraltreatedtaiwanesechronichepatitiscpatientsusingsf36andcldq
AT chungyuehchin assessmentofhealthrelatedqualityoflifeinantiviraltreatedtaiwanesechronichepatitiscpatientsusingsf36andcldq
AT litsaichung assessmentofhealthrelatedqualityoflifeinantiviraltreatedtaiwanesechronichepatitiscpatientsusingsf36andcldq